Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Drotaverine in Dysmenorrhoea Treatment
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 480
- Registration Number
- NCT00292747
- Locations
- 🇭🇺
Sanofi-Aventis, Budapest, Hungary
STILDEP: Zolpidem in Depressive and Dysthimic Patients
- Conditions
- Sleep Initiation and Maintenance DisordersDepression
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 120
- Registration Number
- NCT00292734
- Locations
- 🇭🇺
Sanofi-Aventis, Budapest, Hungary
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
- Conditions
- Stomach Neoplasm
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 610
- Registration Number
- NCT00290966
Rasburicase for Hyperuricemia
- Conditions
- Nutritional and Metabolic Diseases
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00290992
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT00291005
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
- Conditions
- Lung CancerPulmonary NeoplasmsSmall Cell Lung Cancer
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 432
- Registration Number
- NCT00290953
- Locations
- 🇳🇱
Sanofi-aventis adminsitrative office, Gouda, Netherlands
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00290927
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 250
- Registration Number
- NCT00290979
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
- Conditions
- Prostatic HyperplasiaAcute Urinary Retention
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 800
- Registration Number
- NCT00290030
Glulisine Pre- and Postmeal
- Conditions
- Diabetes Mellitus Type 1
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00290043